biostudies-literatureUnknown67(2)Dlugos DJFunded by Longboard Pharmaceuticals (now a part of H. Lundbeck A/S)<h4>Objective</h4>This randomized, double-blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).<h4>Methods</h4>Eligible participants had a DEE diagnosis, were aged 12-65 years, and were taking 1-4 concomitant antiseizure medications. Randomization to treatment groups (4:1 bexicaserin:placebo) was stratified by type of DEE (Dravet syndrome [DS], Lennox-Gastaut syndrome [LGS], or DEE Other). Following a 28-day baseline period, the treatment period consisted of a 15-day flexible uptitration period (6, 9, or 12 mg three times daily, 5 days each) and a 60-day maintenance period on the highest tolerated doEpilepsia646-659https://www.ebi.ac.uk/biostudies/studies/S-EPMC12927688biostudies-literatureBexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).PMC12927688Cunningham EBellinski IZacharia GFroman DMKaladis SHoffman-Huffaker SLSinghal NWalsh BGoodman SOrevillo CJeyachanthiran KGanter SO'Brien TScheffer IELiow KBenbadis SWan EFertig EBatt MSadek Aand the LP352‐201 Study InvestigatorsFarhi AReutens DGroubert HFahey MSamanta DDetyniecki KDlugos DJArain AIrwin KColbert SKuzniecky RHogan RMueller SKaye RBeeler LRenfroe JSchaefer PCieslicki AHashmi SDallas AHenderson VMacken MWaldron JAzevedo MDesai SMari MJVossler DDurgin TShaw SVossler DGPolega SHankins SAboumatar SWolf SRobinson HAnderson AKlein PWharrie RNahouraii RZhu EHart HBiel JGermaine JScheffer IFrench JABurdette DKeough KYe SSmith RAnthony LRobertson HPena PLee KHRiney KfalseBexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC).<h4>Objective</h4>This randomized, double-blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).<h4>Methods</h4>Eligible participants had a DEE diagnosis, were aged 12-65 years, and were taking 1-4 concomitant antiseizure medications. Randomization to treatment groups (4:1 bexicaserin:placebo) was stratified by type of DEE (Dravet syndrome [DS], Lennox-Gastaut syndrome [LGS], or DEE Other). Following a 28-day baseline period, the treatment period consisted of a 15-day flexible uptitration period (6, 9, or 12 mg three times daily, 5 days each) and a 60-day maintenance period on the highest tolerated do2026-01-01T00:00:00Z2026 Feb2026-07-16T17:43:22.153Z2026-07-09T11:09:06.203ZS-EPMC129276884113391210.1111/epi.18689